SMMT Stock Analysis: Summit Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 10.905m USD | 12M Return: -32.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 98.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: under 40 is mostly noise, over 50 gets interesting, and over 70 is strong.
Summit Therapeutics (NASDAQ: SMMT) is a US-headquartered biopharmaceutical company focused on discovering, developing, and commercializing oncology therapies. Its lead candidate, ivonescimab, is a bispecific antibody designed to block PD-1 while simultaneously inhibiting angiogenesis - a dual-target approach that has drawn significant attention across the immuno-oncology field. The drug is being advanced in Phase III trials, both as monotherapy and combined with chemotherapy, for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
The company markets across North America, Europe, Japan, Latin America, the Middle East, and Africa, and was founded in 2003 with headquarters in Miami, Florida. As a clinical-stage biotechnology firm, Summits business model centers on advancing novel biologic candidates through clinical trials, typically relying on partnerships and licensing arrangements rather than operating large-scale commercial manufacturing infrastructure.
- Ivonescimab Phase III data readout against Keytruda in NSCLC
- FDA approval timeline for ivonescimab in lung cancer
- Rising cash burn pressures additional equity capital raises
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.67 > 0.02 and ΔFCF/TA -21.68 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.67 > 3% & CFO -330.7m > Net Income -872.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (775.5m) vs 12m ago 5.06% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.82 (Total Current Assets 467.6m - Total Current Liabilities 63.1m) / Total Assets 491.3m |
| B: -3.83 (Retained Earnings -1.88b / Total Assets 491.3m) |
| C: -2.25 (EBIT TTM -888.5m / Avg Total Assets 394.3m) |
| D: 5.36 (Book Value of Equity 414.0m / Total Liabilities 77.3m) |
| Altman-Z'' = -16.62 = D |
As of July 02, 2026, the stock is trading at USD 14.57 with a total of 5,305,754 shares traded. Over the past week, the price has changed by +0.91%, over one month by -8.47%, over three months by -24.00% and over the past year by -32.17%.
Current recommended Stop Loss: 13.50 (which is 7.3% or 1.2 ATR below the current price).
Summit Therapeutics has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy SMMT.
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.3 | 94.2% |
Market Cap GBP = 8.23b (10.9b USD * 0.7547 USD.GBP)
P/E Forward = 3.7216
P/S = 3891.3077
P/B = 20.1742
Revenue TTM = 0.0 GBP
EBIT TTM = -888.5m GBP
EBITDA TTM = -888.3m GBP
Long Term Debt = 12.8m GBP (estimated: total debt 15.2m - short term 2.41m)
Short Term Debt = 2.41m GBP (from shortTermDebt, last quarter)
Debt = 35.2m GBP (from shortLongTermDebtTotal, last quarter) + Leases 20.0m
Net Debt = -418.8m GBP (calculated: Debt 35.2m - CCE 454.1m)
Enterprise Value = 7.81b GBP (8.23b + Debt 35.2m - CCE 454.1m)
Interest Coverage Ratio = unknown (Ebit TTM -888.5m / Interest Expense TTM 0.0)
EV/FCF = -23.59x (Enterprise Value 7.81b / FCF TTM -331.1m)
FCF Yield = -4.24% (FCF TTM -331.1m / Enterprise Value 7.81b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 108k) / Revenue TTM)
Tobins Q-Ratio = 15.90 (Enterprise Value 7.81b / Total Assets 491.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 35.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -701.9m (EBIT -888.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.41 (Total Current Assets 467.6m / Total Current Liabilities 63.1m)
Debt / Equity = 0.09 (Debt 35.2m / totalStockholderEquity, last quarter 414.0m)
Debt / EBITDA = 0.47 (negative EBITDA) (Net Debt -418.8m / EBITDA -888.3m)
Debt / FCF = 1.26 (negative FCF - burning cash) (Net Debt -418.8m / FCF TTM -331.1m)
Total Stockholder Equity = 309.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -221.2% (out of range, set to none)
RoE = -281.8% (Net Income TTM -872.2m / Total Stockholder Equity 309.5m)
RoCE = -275.7% (out of range, set to none) (EBIT -888.5m / Capital Employed (Equity 309.5m + L.T.Debt 12.8m))
RoIC = -163.0% (out of range, set to none) (NOPAT -701.9m / Invested Capital 430.6m)
WACC = 10.82% (E(8.23b)/V(8.27b) * Re(10.87%) + D(35.2m)/V(8.27b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.62%
[DCF] Fair Price = unknown (Cash Flow -331.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.50 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.22 | Chg30d=+2.89% | Revisions=+14% | Analysts=10
EPS current Year (2026-12-31): EPS=-0.82 | Chg30d=-1.38% | Revisions=-43% | GrowthEPS=+22.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.88 | Chg30d=-2.49% | Revisions=-25% | GrowthEPS=-6.9% | GrowthRev=+1617.3%
[Analyst] Revisions Ratio: -43%